Pomer S
Urologische Universitätsklinik Heidelberg.
Urologe A. 1994 Sep;33(5):370-6.
New approaches to successful prevention and management of transplant rejection include the use of biological immunosuppressants, such as monoclonal antibodies targeting the CD3 and CD4 molecules on native T cells, the interleukin 2 receptor on activated T cells, monocytes and B cells, and adhesion molecules. Several new drugs have been found to be effective immunosuppressive agents: FK 506, a macrolid antibiotic inhibiting lymphokine gene transcription, lymphokine production and secretion, rapamycin, which blocks effects of lymphokine-induced signal transduction, and RS 61443, brequinar and mizoribine, which inhibit DNA/RNA synthesis and lymphocyte proliferation. Initial experience with these drugs clinical protocols currently in use and already devised for use in the near future to test these and other emerging immunosuppressants are reviewed.
成功预防和管理移植排斥反应的新方法包括使用生物免疫抑制剂，例如靶向天然T细胞上的CD3和CD4分子、活化T细胞、单核细胞和B细胞上的白细胞介素2受体以及黏附分子的单克隆抗体。已发现几种新药是有效的免疫抑制剂：FK 506，一种抑制淋巴因子基因转录、淋巴因子产生和分泌的大环内酯类抗生素；雷帕霉素，它阻断淋巴因子诱导的信号转导作用；以及RS 61443、布喹那和咪唑立宾，它们抑制DNA/RNA合成和淋巴细胞增殖。本文综述了目前正在使用以及已设计好在不久的将来用于测试这些和其他新兴免疫抑制剂的临床方案的初步经验。
